Publication details
Dapagliflozin - antidiabetikum, snižující nejen glykémii
| Title in English | Dapagliflozin - antidiabetic, not only reducing blood glucose |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Hypertenze & kardiovaskulární prevence |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | dapagliflozin; SGLT2 inhibitors; diabetes mellitus type 2 |
| Description | Dapagliflozin is a highly selective inhibitor of SGLT2. After his administration is decreased reabsorption of glucose in the proximal tubule. In persons with diabetes reduces glycated hemoglobin of 0.5-1.0% compared to placebo. Dapagliflozin reduces body weight, blood pressure and uric acid. It is indicated as monotherapy or combination therapy, including combination with metformin and insulin. |